MG-132 treatment promotes TRAIL-mediated apoptosis in SEB-1 sebocytes

Area of Science:

• Cell Biology
• Molecular Biology
• Dermatology

Background:

• Sebocytes play a crucial role in skin homeostasis.
• Understanding mechanisms of sebocyte cell death is vital for dermatological research.
• The proteasome inhibitor MG-132 is known to induce apoptosis in various cell types.

Purpose of the Study:

• To elucidate the mechanism by which MG-132 induces cell death in SEB-1 sebocytes.
• To investigate the role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Bcl-2 family members in MG-132-induced sebocyte apoptosis.

Main Methods:

• Apoptosis was assessed using TUNEL staining and flow cytometry (Annexin-FITC/PI).
• Cell viability and proliferation were measured by MTT and CCK-8 assays.
• Protein and gene expression of TRAIL and Bcl-2 family members were analyzed via Western blotting and qPCR.
• RNA interference was employed to knockdown TRAIL and BCL2 Interacting Killer (BIK) mRNA.

Main Results:

• MG-132 treatment significantly increased cell death in SEB-1 sebocytes, but not HaCaT keratinocytes.
• MG-132 elevated TRAIL concentrations in SEB-1 sebocytes, and TRAIL treatment induced dose- and time-dependent cell death.
• Silencing TRAIL or BIK expression using RNA interference restored cell viability in MG-132-treated sebocytes.
• Combined treatment with MG-132 and TRAIL synergistically induced cell death and promoted BIK expression.

Conclusions:

• MG-132 induces cell death in sebocytes primarily through the upregulation of TRAIL and subsequent activation of the BIK pathway.
• The findings highlight a novel mechanism of MG-132-induced apoptosis in sebocytes involving the Bcl-2 family member BIK.
• Targeting the TRAIL/BIK pathway could offer therapeutic strategies for skin conditions involving sebocyte dysregulation.